CoChat
Sign Up
Cited by 15Antibiotic Resistance in BacteriaAntibiotic Use and ResistanceInfections and bacterial resistance

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter species at a large tertiary referral hospital in Lusaka, Zambia

Open access
Kaluba, Ciluvya Kavimba, Samutela, Mulemba Tillika, Kapesa, Christine, Muma, John Bwalya, Hang'ombe, Bernard Mudenda, Hachaambwa, Lottie, Mukomena, Patrice, Yamba, Kaunda·2021·Scientific African
DOI 10.1016/j.sciaf.2021.e00908
Open this paper in CoChat — free account

Abstract

Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter species and are among the leading causes of hospital-acquired infections (HAI). Treating patients with HAI caused by these pathogens is usually a challenge due to intrinsic and acquired resistance to the commonly used and affordable antibiotics, which has been heightened by the emergence of metallo-β lactamases thereby exhibiting resistance to carbapenems. Currently, carbapenem resistance represents an increasing problem in the health care settings globally but there is still a paucity of data on carbapenem resistance in our setting. To detect carbapenem resistance and the susceptibility to other antimicrobial agents in P. aeruginosa and Acinetobacter species isolated from blood, sputum, skin and soft tissue specimens between March, 2018 and June, 2019 at the University Teaching Hospital (UTH), Lusaka, Zambia. This was a retrospective hospital based study, involving routine blood, sputum, skin and soft tissue samples submitted to the microbiology laboratory. Conventional microbiology methods were used to identify the organisms, while Kirby-Bauer disc diffusion method was used to determine the antimicrobial susceptibility profiles of the isolates. In order to detect carbapenemase production in P. aeruginosa isolates that were resistant to imipenem by disc diffusion, the isolates were subjected to the modified carbapenem inactivation method (mCIM) method. A total of 384 samples were analyzed, of which 84 P. aeruginosa and 11 Acinetobacter species were isolated. The P. aeruginosa isolates were susceptible to imipenem (94%), piperacillin-tazobactum (95.2%), amikacin (91%), ciprofloxacin (69%), gentamicin (63.1%) and ceftazidime (51.2%). The Acinetobacter species isolates were most susceptible to amikacin (90.9%), imipenem (82.9%) and piperacillin-tazobactum (82.8%), ciprofloxacin, tetracycline and cefepime all at 27.3% each but had the lowest susceptibility at 9.1% to both gentamicin and cefotaxime. Carbapenem resistance in P. aeruginosa was 5/84 (6%) and 2/11 (18.2%) in Acinetobacter species. Carbapenemase production was confirmed in all five P. aeruginosa isolates. Carbapenem resistance was low in both organisms demonstrating that imipenem is still an effective treatment choice for invasive infections caused by these organisms in our setting. In order to reduce HAI and improve patient outcome, there is need to strengthen antimicrobial surveillance/stewardship and infection control at the UTH.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.sciaf.2021.e00908

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 31

  1. Mehrad, 2015, Antimicrobial resistance in hospital-acquired gram-negative bacterial infections, Chest, 147, 1413, 10.1378/chest.14-2171 · DOI
  2. Peleg, 2010, Hospital-acquired infections due to gram-negative bacteria, N. Engl. J. Med., 362, 1804, 10.1056/NEJMra0904124 · DOI
  3. Haque, 2018, Health care-associated infections-an overview, Infect. Drug Resist., 10.2147/IDR.S177247 · DOI
  4. Zaidi, 2005, Hospital-acquired neonatal infections in developing countries, Lancet, 365, 1175, 10.1016/S0140-6736(05)71881-X · DOI · Paper page
  5. Arabi, 2008, Ventilator-associated pneumonia in adults in developing countries: a systematic review, Canada Int. J. Infect. Dis., 12, 505, 10.1016/j.ijid.2008.02.010 · DOI
  6. Garnacho-Montero, 2010, Multiresistant Acinetobacter baumannii infections: epidemiology and management, Curr. Opin. Infect. Dis., 23, 332, 10.1097/QCO.0b013e32833ae38b · DOI
  7. Alekshun, 2007, Molecular mechanisms of antibacterial multidrug resistance, Cell, 128, 1037, 10.1016/j.cell.2007.03.004 · DOI
  8. Li X.Z., Livermore D.M., Nikaidol H., et al. Role of efflux pump(s) in intrinsic resistance of pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. 1994. · DOI
  9. Vila J., Martí S., Nchez-Céspedes Sá Porins J., Efflux pumps and multidrug resistance in Acinetobacter baumannii. [cited 2020 Mar 29];Available from: https://academic.oup.com/jac/article-abstract/59/6/1210/711566 · DOI
  10. Noyal, 2009, Simple screening tests for detection of carbapenemases in clinical isolates of nonfermentative Gram-negative bacteria, Indian J. Med. Res., 129, 707
  11. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. [cited 2020 Mar 30];Available from: http://tai.sagepub.com
  12. Kateete, 2017, Genotypic diversity among multidrug resistant Pseudomonas aeruginosa and Acinetobacter species at Mulago Hospital in Kampala, Uganda, BMC Res. Notes, 10, 1, 10.1186/s13104-017-2612-y · DOI
  13. De Francesco, 2013, Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital, J. Infect. Public Health, 6, 179, 10.1016/j.jiph.2012.11.006 · DOI
  14. Alemayehu T., Ali M., Mitiku E., Hailemariam M. The burden of antimicrobial resistance at tertiary care hospital, southern Ethiopia: a three years’ retrospective study. [cited 2020 Apr 9];Available from: 10.1186/s12879-019-4210-1 · DOI
  15. Lautenbach, 2009, Epidemiology and Impact of imipenem resistance in Acinetobacter baumannii, Infect. Control Hosp. Epidemiol., 30, 1186, 10.1086/648450 · DOI
  16. Chung, 2011, High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia, Am. J. Respir. Crit. Care Med., 184, 1409, 10.1164/rccm.201102-0349OC · DOI
  17. Ramadan, 2018, Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations, Infect. Drug Resist., 11, 1261, 10.2147/IDR.S170233 · DOI
  18. Ballouz, 2017, Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia, Front. Cell. Infect. Microbiol. [Internet], 7, 156, 10.3389/fcimb.2017.00156 · DOI
  19. Dahdouh, 2016, Acinetobacter baumannii isolated from lebanese patients: phenotypes and genotypes of resistance, clonality, and determinants of pathogenicity, Front. Cell. Infect. Microbiol. [Internet], 6, 163
  20. Kindu M., Derseh L., Gelaw B., Moges F. Carbapenemase-producing non-glucose-fermenting gram-negative Bacilli in Africa, Pseudomonas aeruginosa and Acinetobacter baumannii: a systematic review and meta-analysis. 2020 [cited 2021 Feb 17];Available from: 10.1155/2020/9461901 · DOI
  21. Tan, 2015, Correlation between antibiotic consumption and carbapenem-resistant Acinetobacter baumannii causing health care-associated infections at a hospital from 2005 to 2010, J. Microbiol. Immunol. Infect., 48, 540, 10.1016/j.jmii.2014.02.004 · DOI
  22. Sefraoui, 2014, Molecular epidemiology of Carbapenem-resistant Pseudomonas aeruginosa clinical strains isolated from western Algeria between 2009 and 2012, Microb. Drug Resist., 20, 156, 10.1089/mdr.2013.0161 · DOI
  23. Terahara, 2019, Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study, J. Int. Med. Res., 47, 4711, 10.1177/0300060519864181 · DOI
  24. Yang, 2018, Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014, Antimicrob. Resist. Infect. Control, 7, 137, 10.1186/s13756-018-0430-1 · DOI
  25. Wangai I.D.F.K., Masika M.M., Lule G.N., Karari E.M., MaritimID M.C., Jaoko W.G., et al. Bridging antimicrobial resistance knowledge gaps: the east African perspective on a global problem. 2019 [cited 2020 Mar 29];Available from: 10.1371/journal.pone.0212131 · DOI
  26. Kock, 2013, Prevalence of carbapenem resistance genes in Acinetobacter baumannii isolated from clinical specimens obtained from an academic hospital in South Africa, S. Afr. J. Epidemiol. Infect., 28, 28
  27. Sturkenboom, 2018, Amikacin dosing for MDR tuberculosis: a systematic review to establish or revise the current recommended dose for tuberculosis treatment, Clin. Infect. Dis., 67, S303, 10.1093/cid/ciy613 · DOI
  28. Manyi-Loh, 2018, Antibiotic use in agriculture and its consequential resistance in environmental sources: Potential public health implications [Internet], Molecules, 23, 10.3390/molecules23040795 · DOI · Paper page
  29. Hu, 2019, Risk factors for carbapenem-resistant pseudomonas aeruginosa, Zhejiang Province, China, Emerg. Infect. Dis., 25, 1861, 10.3201/eid2510.181699 · DOI
  30. Olayinka, 2004, Prevalence of multi-drug resistant (Mdr) pseudomonas aeruginosa isolates in surgical units of Ahmadu Bello University Teaching Hospital, Zaria, Nigeria : an Indication for effective control measures, Ann. Afr. Med., 3, 13
  31. Matar, 2018, Editorial: Pseudomonas and Acinetobacter: from drug resistance to pathogenesis, Front. Cell. Infect. Microbiol., 8, 1, 10.3389/fcimb.2018.00068 · DOI

Cited by

Sorted by citations

See all 15

Metadata

Authors
Kaluba, C. K., Samutela, M. T., Kapesa, C., Muma, J. B., Hang'ombe, B. M., Hachaambwa, L., Mukomena, P., & Yamba, K.
Affiliations
  • University of Zambia (ZM)
  • University Teaching Hospital (ZM)
  • University of Maryland, Baltimore (US)
Corresponding author
Yamba, Kaunda
ORCID
Venue
Scientific African
Publisher
Elsevier BV
Published
2021-09
Volume
13
Pages
e00908
ISSN
2468-2276 (ISSN-L)
DOI
10.1016/j.sciaf.2021.e00908
OpenAlex
W3185099491
Cited by
15
References
1
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1
FWCI
0.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific African (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
Keywords
carbapenem resistance, Pseudomonas aeruginosa, Acinetobacter, nosocomial infections, metallo-beta-lactamase, carbapenemase production, antimicrobial susceptibility, imipenem resistance, modified carbapenem inactivation method, Lusaka, Zambia, tertiary care hospital, skin and soft tissue infections, blood culture isolates, sputum isolates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter species at a large tertiary referral hospital in Lusaka, Zambia. https://app.cochat.ai/papers/10.1016/j.sciaf.2021.e00908
The paper
Kaluba, C. K., Samutela, M. T., Kapesa, C., Muma, J. B., Hang'ombe, B. M., Hachaambwa, L., Mukomena, P., & Yamba, K. (2021). Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter species at a large tertiary referral hospital in Lusaka, Zambia. Scientific African. https://doi.org/10.1016/j.sciaf.2021.e00908